EPA has completed its review of public comments on the most recent revised human health and ecological risk assessments and is issuing its risk management decisions for oxamyl. The decisions outlined in this document do not include the final tolerance reassessment decision for oxamyl; however, some tolerance actions will be undertaken prior to completion of the final tolerance reassessment. The final tolerance reassessment decision (e.g., revocation or other administrative actions) for this chemical will be issued once the Agency determines the scope of cumulative assessment that is needed. The Agency may need to pursue further risk management measures for oxamyl once the cumulative assessment is finalized. The revised risk assessments are based on review of the data required to support the use patterns of currently registered products. The Agency invited stakeholders to provide proposals, ideas, or suggestions on appropriate mitigation measures before the Agency issued its risk mitigation decision on oxamyl. After considering the risks in the revised assessments, as well as mitigation proposed by DuPont de Nemours, Incorporated (the sole registrant of oxamyl), and comments and mitigation suggestions from other interested parties, EPA developed its risk management decision for uses of oxamyl that pose risks of concern. This decision is discussed fully in this document.